Research output

Research output per year 1989 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

• 464 Article
• 75 Review article
• 42 Letter
• 17 Comment/debate
• 22 More
  • 12 Chapter
  • 5 Editorial
  • 2 Foreword/postscript
  • 2 Short survey
  • 1 Book

Research output per year

Research output per year

Search results

• 2024

  Day 100 Natural Killer Cell/CD14+HLA-DR^DIM ratio and survival in lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation

  Porrata, L. F., Ansell, S. M., Micallef, I., Johnston, P. B., Villasboas Bisneto, J., Paludo, J., Durani, U. & Markovic, S. N., Jan 2024, In: Clinical Transplantation. 38, 1, e15211.

  Research output: Contribution to journal › Article › peer-review

  • Peripheral Blood Stem Cell Transplantation 100%
  • Hematopoietic Stem Cell Transplantation 80%
  • Natural Killer Cells 69%
  • Lymphoma 62%
  • Progression-Free Survival 48%

• Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments

  Krull, J. E., Wenzl, K., Hopper, M. A., Manske, M. K., Sarangi, V., Maurer, M. J., Larson, M. C., Mondello, P., Yang, Z. Z., Novak, J. P., Serres, M., Whitaker, K. R., Villasboas Bisneto, J. C., Habermann, T. M., Witzig, T. E., Link, B. K., Rimsza, L. M., King, R. L., Ansell, S. M., Cerhan, J. R., & 1 othersNovak, A. J., Mar 19 2024, In: Cell Reports Medicine. 5, 3, 101443.

  Research output: Contribution to journal › Article › peer-review

  Open Access

• Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapy

  Burlile, J. F., Frechette, K. M., Breen, W. G., Hwang, S. R., Higgins, A. S., Nedved, A. N., Harmsen, W. S., Pulsipher, S. D., Witzig, T. E., Micallef, I. N., Hoppe, B. S., Habermann, T. M., Thanarajasingam, G., Johnston, P. B., Inwards, D. J., Bennani, N. N., Peterson, J. L., Stish, B. J., Rule, W., Ansell, S. M., & 1 othersLester, S. C., Mar 12 2024, In: Blood Advances. 8, 5, p. 1250-1267 18 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

• Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy

  Xie, Z., Lasho, T., Khurana, A., Ferrer, A., Finke, C., Mangaonkar, A. A., Ansell, S., Fernandez, J., Shah, M. V., Al-Kali, A., Gangat, N., Abeykoon, J., Witzig, T. E. & Patnaik, M. M., Feb 2024, In: Haematologica. 109, 2, p. 509-520 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Radioimmunotherapy 100%
  • Follicular Lymphoma 88%
  • Second Primary Neoplasms 82%
  • Hematopoiesis 78%
  • Mutation 15%

• Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clinic experience

  Chohan, K. L., Bansal, R., Hathcock, M. A., Paludo, J., Bennani, N. N., Johnston, P. B., Khurana, A., Durani, U., Wang, Y., Ruff, M. W., Villasboas Bisneto, J. C., Ansell, S. M., Lin, Y. & Kenderian, S. S., 2024, In: Leukemia and Lymphoma. 65, 3, p. 389-393 5 p.

  Research output: Contribution to journal › Letter › peer-review

• Serial Evaluation of Preimmunization Antibody Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy

  Bansal, R., Vergidis, P., Tosh, P. K., Wilson, J., Hathcock, M., Khurana, A., Bennani, N. N., Paludo, J., Villasboas, J. C., Wang, Y., Ansell, S. M., Johnston, P. B., Freeman, C. & Lin, Y., Apr 2024, In: Transplantation and Cellular Therapy. 30, 4, p. 455.e1-455.e7

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chimeric Antigen Receptors 100%
  • Cell- and Tissue-Based Therapy 70%
  • Lymphoma 61%
  • T-Lymphocytes 45%
  • Antibodies 41%

• The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma

  Laoruangroj, C., Atherton, P. J., Wiseman, G. A., Ansell, S., Feldman, A. L., Schumacher, P. & Witzig, T. E., 2024, In: Leukemia and Lymphoma. 65, 3, p. 333-338 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • ibritumomab tiuxetan 100%
  • Radioimmunotherapy 84%
  • Follicular Lymphoma 74%
  • Rituximab 65%
  • Immunotherapy 53%
• 2023

  Anaplastic large cell lymphomas with equivocal DUSP22 FISH results: recommendations for clinical reporting and diagnostic evaluation

  Fadl, A., Oishi, N., Shi, M., Dasari, S., Ansell, S. M., Ketterling, R. P. & Feldman, A. L., Nov 2023, In: Human Pathology. 141, p. 6-14 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Anaplastic Large-Cell Lymphoma 100%
  • Fluorescence In Situ Hybridization 75%
  • Immunohistochemistry 34%
  • T-Cell Lymphoma 14%
  • Color 10%

• Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy

  Bezerra, E. D., Iqbal, M., Munoz, J., Khurana, A., Wang, Y., Maurer, M. J., Bansal, R., Hathcock, M. A., Bennani, N., Murthy, H. S., Rosenthal, A. C., Paludo, J., Villasboas, J. C., Johnston, P. B., Habermann, T. M., Ansell, S. M., Castro, J. E., Witzig, T. E., Kharfan-Dabaja, M. A., Nowakowski, G. S., & 1 othersLin, Y., Apr 25 2023, In: Blood Advances. 7, 8, p. 1572-1576 5 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

• Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma

  Desai, S. H., Mwangi, R., Smith, A. N., Maurer, M. J., Farooq, U., King, R. L., Cerhan, J. R., Feldman, A. L., Habermann, T. M., Thompson, C. A., Wang, Y., Ansell, S. M., Witzig, T. E. & Nowakowski, G. S., Feb 2023, In: Hematological Oncology. 41, 1, p. 39-49 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lymphoma, Large B-Cell, Diffuse 100%
  • Lymphoma 73%
  • Gene Expression Profiling 33%
  • Immunohistochemistry 22%
  • B-Lymphocytes 18%

• Central nervous system involvement (Bing-Neel Syndrome) in patients with Waldenström macroglobulinemia

  Zanwar, S., Abeykoon, J. P., Ansell, S. M., Gertz, M. A., Mauermann, M., Witzig, T. E., Johnston, P., Kyle, R. A., King, R. L., Habermann, T. M., Kumar, S. & Kapoor, P., 2023, In: Leukemia and Lymphoma. 64, 8, p. 1490-1493 4 p.

  Research output: Contribution to journal › Letter › peer-review

• Central nervous system involvement by mantle cell lymphoma

  McLaughlin, N., Wang, Y., Witzig, T., Villasboas, J., Habermann, T., Inwards, D., Bennani, N., Thanarajasingam, G., Nowakowski, G., Porrata, L., Thompson, C., Micallef, I., Johnston, P., Ansell, S. & Paludo, J., 2023, In: Leukemia and Lymphoma. 64, 2, p. 371-377 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Mantle-Cell Lymphoma 100%
  • Central Nervous System 56%
  • Control Groups 4%
  • Therapeutics 1%

• Characterization of immune exhaustion and suppression in the tumor microenvironment of splenic marginal zone lymphoma

  Anagnostou, T., Yang, Z. Z., Jalali, S., Kim, H. J., Larson, D. P., Tang, X., Yu, Y., Pritchett, J. C., Bisneto, J. V., Price-Troska, T. L., Mondello, P., Novak, A. J. & Ansell, S. M., Jul 2023, In: Leukemia. 37, 7, p. 1485-1498 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Tumor Microenvironment 100%
  • Lymphoma 80%
  • T-Lymphocytes 26%
  • Spleen 24%
  • Regulatory T-Lymphocytes 21%

• Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma

  Desai, S. H., Spinner, M. A., David, K., Bachanova, V., Goyal, G., Kahl, B., Dorritie, K., Azzi, J., Kenkre, V. P., Arai, S., Chang, C., Fusco, B., Sumransub, N., Hatic, H., Saba, R., Ibrahim, U., Harris, E. I., Shah, H., Murphy, J., Ansell, S., & 10 othersJagadish, D., Orellana-noia, V., Diefenbach, C., Iyenger, S., Rappazzo, K. C., Mishra, R., Choi, Y., Nowakowski, G. S., Advani, R. H. & Micallef, I. N., Mar 2023, In: American journal of hematology. 98, 3, p. 464-471 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Hodgkin Disease 100%
  • Brentuximab Vedotin 90%
  • Progression-Free Survival 88%
  • Stem Cells 71%
  • Transplants 60%

• Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma

  Saifi, O., Breen, W. G., Lester, S. C., Rule, W. G., Stish, B. J., Rosenthal, A., Munoz, J., Lin, Y., Bansal, R., Hathcock, M. A., Johnston, P. B., Ansell, S. M., Paludo, J., Khurana, A., Villasboas, J. C., Wang, Y., Iqbal, M., Moustafa, M. A., Murthy, H. S., Kharfan-Dabaja, M. A., & 2 othersPeterson, J. L. & Hoppe, B. S., Nov 2023, In: Haematologica. 108, 11, p. 2982-2992 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Adoptive Immunotherapy 100%
  • Non-Hodgkin's Lymphoma 71%
  • Radiotherapy 52%
  • Progression-Free Survival 30%
  • Recurrence 28%

• Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes (Leukemia, (2022), 36, 12, (2835-2844), 10.1038/s41375-022-01711-0)

  Berndt, S. I., Vijai, J., Benavente, Y., Camp, N. J., Nieters, A., Wang, Z., Smedby, K. E., Kleinstern, G., Hjalgrim, H., Besson, C., Skibola, C. F., Morton, L. M., Brooks-Wilson, A. R., Teras, L. R., Breeze, C., Arias, J., Adami, H. O., Albanes, D., Anderson, K. C., Ansell, S. M., & 120 othersBassig, B., Becker, N., Bhatti, P., Birmann, B. M., Boffetta, P., Bracci, P. M., Brennan, P., Brown, E. E., Burdett, L., Cannon-Albright, L. A., Chang, E. T., Chiu, B. C. H., Chung, C. C., Clavel, J., Cocco, P., Colditz, G., Conde, L., Conti, D. V., Cox, D. G., Curtin, K., Casabonne, D., De Vivo, I., Diepstra, A., Diver, W. R., Dogan, A., Edlund, C. K., Foretova, L., Fraumeni, J. F., Gabbas, A., Ghesquières, H., Giles, G. G., Glaser, S., Glenn, M., Glimelius, B., Gu, J., Habermann, T. M., Haiman, C. A., Haioun, C., Hofmann, J. N., Holford, T. R., Holly, E. A., Hutchinson, A., Izhar, A., Jackson, R. D., Jarrett, R. F., Kaaks, R., Kane, E., Kolonel, L. N., Kong, Y., Kraft, P., Kricker, A., Lake, A., Lan, Q., Lawrence, C., Li, D., Liebow, M., Link, B. K., Magnani, C., Maynadie, M., McKay, J., Melbye, M., Miligi, L., Milne, R. L., Molina, T. J., Monnereau, A., Montalvan, R., North, K. E., Novak, A. J., Onel, K., Purdue, M. P., Rand, K. A., Riboli, E., Riby, J., Roman, E., Salles, G., Sborov, D. W., Severson, R. K., Shanafelt, T. D., Smith, M. T., Smith, A., Song, K. W., Song, L., Southey, M. C., Spinelli, J. J., Staines, A., Stephens, D., Sutherland, H. J., Tkachuk, K., Thompson, C. A., Tilly, H., Tinker, L. F., Travis, R. C., Turner, J., Vachon, C. M., Vajdic, C. M., Van Den Berg, A., Van Den Berg, D. J., Vermeulen, R. C. H., Vineis, P., Wang, S. S., Weiderpass, E., Weiner, G. J., Weinstein, S., Doo, N. W., Ye, Y., Yeager, M., Yu, K., Zeleniuch-Jacquotte, A., Zhang, Y., Zheng, T., Ziv, E., Sampson, J., Chatterjee, N., Offit, K., Cozen, W., Wu, X., Cerhan, J. R., Chanock, S. J., Slager, S. L. & Rothman, N., Oct 2023, In: Leukemia. 37, 10, p. 2142 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Genetic Profile 100%
  • Genetic Predisposition to Disease 78%
  • Netherlands 74%
  • Non-Hodgkin's Lymphoma 72%
  • Leukemia 63%

• Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma

  Saifi, O., Breen, W. G., Lester, S. C., Rule, W. G., Stish, B. J., Rosenthal, A., Munoz, J., Lin, Y., Bansal, R., Hathcock, M. A., Bennani, N. N., Paludo, J., Khurana, A., Villasboas, J. C., Johnston, P. B., Ansell, S. M., Iqbal, M., Moustafa, M. A., Murthy, H. S., Kharfan-Dabaja, M. A., & 2 othersHoppe, B. S. & Peterson, J. L., Aug 1 2023, In: International Journal of Radiation Oncology Biology Physics. 116, 5, p. 999-1007 9 p.

  Research output: Contribution to journal › Article › peer-review

  • horses 100%
  • Chimeric Antigen Receptors 95%
  • Adoptive Immunotherapy 92%
  • antigens 89%
  • B-Cell Lymphoma 73%

• End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET

  Chohan, K. L., Young, J. R., Lester, S., Moustafa, M. A., Rosenthal, A., Tun, H. W., Hoppe, B. S., Johnston, P. B., Micallef, I. N., Habermann, T. M. & Ansell, S. M., Jun 2023, In: Haematologica. 108, 6, p. 1697-1701 5 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study

  Bock, A. M., Gile, J. J., Larson, M. C., Poonsombudlert, K., Tawfiq, R. K., Maliske, S., Maurer, M. J., Kabat, B. F., Paludo, J., Inwards, D. J., Ayyappan, S., Link, B. K., Ansell, S. M., Habermann, T. M., Witzig, T. E., Nowakowski, G. S., Cerhan, J. R., Farooq, U. & Wang, Y., Dec 2023, In: Blood cancer journal. 13, 1, 169.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Mantle-Cell Lymphoma 100%
  • Cohort Studies 52%
  • Prospective Studies 48%
  • Therapeutics 12%
  • Survival 7%

• Exploring Gene Expression Profiles in Primary Central Nervous System Vasculitis

  Salvarani, C., Paludo, J., Hunder, G. G., Ansell, S. M., Giannini, C., Parisi, J. E., Huston, J., Koster, M. J., Warrington, K. J., Croci, S. & Brown, R. D., Jan 2023, In: Annals of neurology. 93, 1, p. 120-130 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Central Nervous System Vasculitis 100%
  • Vasculitis 69%
  • Transcriptome 62%
  • RNA Sequence Analysis 21%
  • Brain 19%

• Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II–IV peripheral T-cell lymphoma

  Stuver, R., Horwitz, S. M., Advani, R. H., Vose, J. M., Lee, H. J., Mehta-Shah, N., Zain, J. M., Haverkos, B., Lechowicz, M. J., Moskowitz, A. J., Pham, L. Q., Leyden, E., Ansell, S. M. & Lunning, M. A., Aug 2023, In: British journal of haematology. 202, 3, p. 525-529 5 p.

  Research output: Contribution to journal › Article › peer-review

  • Peripheral T-Cell Lymphoma 100%
  • Lenalidomide 97%
  • Therapeutics 11%
  • Febrile Neutropenia 11%
  • Progression-Free Survival 8%

• Long-term outcomes for patients with Hodgkin lymphoma at increased risk of progression or relapse

  Kosydar, S. & Ansell, S. M., 2023, In: Leukemia and Lymphoma. 64, 1, p. 5-17 13 p.

  Research output: Contribution to journal › Review article › peer-review

  • Hodgkin Disease 100%
  • Recurrence 55%
  • Immunoconjugates 18%
  • Risk Management 15%
  • Therapeutics 11%

• Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity

  Breen, W. G., Young, J. R., Hathcock, M. A., Kowalchuk, R. O., Thorpe, M. P., Bansal, R., Khurana, A., Bennani, N. N., Paludo, J., Bisneto, J. V., Wang, Y., Ansell, S. M., Peterson, J. L., Johnston, P. B., Lester, S. C. & Lin, Y., Dec 2023, In: Blood cancer journal. 13, 1, 127.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • axicabtagene ciloleucel 100%
  • Chimeric Antigen Receptors 69%
  • Non-Hodgkin's Lymphoma 48%
  • Tumor Burden 40%
  • Leukapheresis 35%

• Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies

  Bhardwaj, V. & Ansell, S. M., 2023, In: Frontiers in Cell and Developmental Biology. 11, 1129343.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Myeloid-Derived Suppressor Cells 100%
  • Hematologic Neoplasms 76%
  • T-Lymphocytes 46%
  • Immunosuppressive Agents 27%
  • Myelopoiesis 11%

• Molecular classification and identification of an aggressive signature in low-grade B-cell lymphomas

  Hopper, M. A., Wenzl, K., Hartert, K. T., Krull, J. E., Dropik, A. R., Novak, J. P., Manske, M. K., Serres, M. K. R., Sarangi, V., Larson, M. C., Maurer, M. J., Yang, Z. Z., Paludo, J., McPhail, E. D., Habermann, T. M., Link, B. K., Rimsza, L. M., Ansell, S. M., Cerhan, J. R., Jevremovic, D., & 1 othersNovak, A. J., Oct 2023, In: Hematological Oncology. 41, 4, p. 644-654 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • B-Cell Lymphoma 100%
  • Non-Hodgkin's Lymphoma 91%
  • cdc Genes 30%
  • Whole Exome Sequencing 28%
  • Machine Learning 27%

• Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies

  Mondello, P., Paludo, J., Novak, J. P., Wenzl, K., Yang, Z. Z., Jalali, S., Krull, J. E., Braggio, E., Dasari, S., Manske, M. K., Abeykoon, J. A., Sarangi, V., Kapoor, P., Paulus, A., Reeder, C. B., Ailawadhi, S., Chanan-Khan, A. A., Kyle, R. A., Gertz, M. A., Novak, A. J., & 1 othersAnsell, S. M., Mar 1 2023, In: Clinical Cancer Research. 29, 5, p. 957-970 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Waldenstrom Macroglobulinemia 100%
  • Paraproteinemias 91%
  • Monoclonal Gammopathy of Undetermined Significance 83%
  • Immunoglobulin M 65%
  • Metabolomics 32%

• Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study

  Ansell, S. M., Bröckelmann, P. J., von Keudell, G., Lee, H. J., Santoro, A., Zinzani, P. L., Collins, G. P., Cohen, J. B., de Boer, J. P., Kuruvilla, J., Savage, K. J., Trněný, M., Provencio, M., Jäger, U., Willenbacher, W., Wen, R., Akyol, A., Mikita-Geoffroy, J., Shipp, M. A., Engert, A., & 1 othersArmand, P., Oct 24 2023, In: Blood Advances. 7, 20, p. 6266-6274 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Nivolumab 100%
  • Hodgkin Disease 75%
  • Brentuximab Vedotin 58%
  • Cell Transplantation 52%
  • Survival 40%

• Outcomes of Older Adults with Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation: A Mayo Clinic Cohort Analysis

  Wudhikarn, K., Johnson, B. M., Inwards, D. J., Porrata, L. F., Micallef, I. N., Ansell, S. M., Hogan, W. J., Paludo, J., Villasboas, J. C. & Johnston, P. B., Mar 2023, In: Transplantation and Cellular Therapy. 29, 3, p. 176.e1-176.e8

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Stem Cell Transplantation 100%
  • Non-Hodgkin's Lymphoma 90%
  • Cohort Studies 65%
  • Lymphoma 33%
  • Cell Transplantation 17%

• Outcomes of Patients with Classic Hodgkin Lymphoma Who Relapsed after Autologous Stem Cell Transplant

  Tun, A. M., Wang, Y., Matin, A., Inwards, D. J., Habermann, T. M., Micallef, I., Johnston, P. B., Porrata, L., Paludo, J., Bisneto, J. V., Rosenthal, A., Tun, H. W., Cerhan, J. R., Witzig, T. E., Nowakowski, G. S. & Ansell, S. M., Apr 4 2023, In: HemaSphere. 7, 4, p. E869

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hodgkin Disease 100%
  • Stem Cells 71%
  • Transplants 60%
  • Brentuximab Vedotin 58%
  • Progression-Free Survival 55%

• Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era

  Desai, S. H., Spinner, M. A., Evens, A. M., Sykorova, A., Bachanova, V., Goyal, G., Kahl, B., Dorritie, K., Azzi, J., Kenkre, V. P., Chang, C., Michalka, J., Ansell, S. M., Fusco, B., Sumransub, N., Hatic, H., Saba, R., Ibrahim, U., Harris, E. I., Shah, H., & 14 othersWagner-Johnston, N., Arai, S., Nowakowski, G. S., Mocikova, H., Jagadeesh, D., Blum, K. A., Diefenbach, C., Iyengar, S., Rappazzo, K. C., Baidoun, F., Choi, Y., Prochazka, V., Advani, R. H. & Micallef, I., Dec 12 2023, In: Blood Advances. 7, 23, p. 7295-7303 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hodgkin Disease 100%
  • Stem Cells 71%
  • Brentuximab Vedotin 62%
  • Transplants 60%
  • Survival 53%

• Poly-lymphomatous Syndrome With Concurrent or Sequential Hodgkin and Non-Hodgkin lymphoma

  Iqbal, M., Jiang, L., Li, K. D., Moustafa, M. A., Kimbrough, E. M. O., Ansell, S. M. & Tun, H. W., Feb 2023, In: Clinical Lymphoma, Myeloma and Leukemia. 23, 2, p. 138-144 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Hodgkin Disease 100%
  • Non-Hodgkin's Lymphoma 91%
  • Lymphoma 22%
  • Biopsy 10%
  • Therapeutics 5%

• Precision cancer therapies

  O'Connor, O. A., Ansell, S. M. & Seymour, J. F., Apr 14 2023, Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice. wiley, Vol. 1. p. 1-482 482 p.

  Research output: Chapter in Book/Report/Conference proceeding › Chapter

  • Neoplasms 100%
  • Epigenome 70%
  • Private Sector 69%
  • Drug Delivery Systems 55%
  • Therapeutics 50%

• Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma

  Acosta-Medina, A. A., Johnson, I. M. K., Bansal, R., Hathcock, M., Kenderian, S. J., Durani, U., Khurana, A., Wang, Y., Paludo, J., Villasboas, J. C., Bennani, N. N., Johnston, P. B., Ansell, S. M., Lin, Y. & Alkhateeb, H. B., Dec 2023, In: Blood cancer journal. 13, 1, 7.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T-cell therapy recipients

  Powell, M. Z., Mara, K. C., Bansal, R., Hathcock, M. A., Khurana, A., Bennani, N. N., Wang, Y., Paludo, J., Bisneto, J. V., Ansell, S. M., Johnston, P. B., Lin, Y. & Barreto, J. N., Apr 2023, In: Cancer medicine. 12, 8, p. 9228-9235 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chimeric Antigen Receptors 100%
  • Procalcitonin 94%
  • Cell- and Tissue-Based Therapy 70%
  • Bacterial Infections 69%
  • Biomarkers 48%

• Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials

  Tam, C. S., Kapoor, P., Castillo, J. J., Buske, C., Ansell, S. M., Branagan, A. R., Kimby, E., Li, Y., Palomba, M. L., Qiu, L., Shadman, M., Abeykoon, J. P., Sarosiek, S., Vos, J. M. I., Yi, S., Stephens, D., Roos-Weil, D., Roccaro, A. M., Morel, P., Munshi, N. C., & 6 othersAnderson, K. C., San-Miguel, J., Garcia-Sanz, R., Dimopoulos, M. A., Treon, S. P. & Kersten, M. J., Mar 2023, In: Seminars in Hematology. 60, 2, p. 118-124 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Waldenstrom Macroglobulinemia 100%
  • Clinical Trials 47%
  • Education 46%
  • Rituximab 39%
  • Bendamustine Hydrochloride 28%

• Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma

  Wiedmeier-Nutor, J. E., Iqbal, M., Rosenthal, A. C., Bezerra, E. D., Garcia-Robledo, J. E., Bansal, R., Johnston, P. B., Hathcock, M., Larsen, J. T., Bergsagel, P. L., Wang, Y., Reeder, C. B., Leis, J. F., Fonseca, R., Palmer, J. M., Gysbers, B. J., Mwangi, R., Warsame, R. M., Kourelis, T., Hayman, S. R., & 15 othersDingli, D., Kapoor, P., Kumar, S. K., Durani, U., Villasboas, J. C., Paludo, J., Bennani, N. N., Nowakowski, G., Ansell, S. M., Castro, J. E., Kharfan-Dabaja, M. A., Lin, Y., Vergidis, P., Murthy, H. S. & Munoz, J., Jun 2023, In: Clinical Lymphoma, Myeloma and Leukemia. 23, 6, p. 456-462 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chimeric Antigen Receptors 100%
  • Multiple Myeloma 73%
  • Cell- and Tissue-Based Therapy 70%
  • Non-Hodgkin's Lymphoma 69%
  • Vaccination 59%

• Secreted ORF8 induces monocytic pro-inflammatory cytokines through NLRP3 pathways in patients with severe COVID-19

  Wu, X., Manske, M. K., Ruan, G. J., Witter, T. L., Nowakowski, K. E., Abeykoon, J. P., Tang, X., Yu, Y., Gwin, K. A., Wu, A., Taupin, V., Bhardwaj, V., Paludo, J., Dasari, S., Dong, H., Ansell, S. M., Badley, A. D., Schellenberg, M. J. & Witzig, T. E., Jun 16 2023, In: iScience. 26, 6, 106929.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Pyrin Domain 100%
  • NLR Proteins 98%
  • Open Reading Frames 64%
  • SARS Virus 49%
  • Cytokines 41%

• SOHO State of the Art Updates and Next Questions | From Biology to Therapy: Progress in Hodgkin Lymphoma

  Chohan, K. L. & Ansell, S. M., Oct 2023, In: Clinical Lymphoma, Myeloma and Leukemia. 23, 10, p. 705-713 9 p.

  Research output: Contribution to journal › Review article › peer-review

  • Hodgkin Disease 100%
  • Brentuximab Vedotin 31%
  • Bispecific Antibodies 27%
  • Chimeric Antigen Receptors 26%
  • Immunoconjugates 25%

• Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experience

  Chohan, K. L., Paludo, J., Vallumsetla, N., Larson, D., King, R. L., He, R., Gonsalves, W., Inwards, D., Witzig, T. E., Swaika, A., Jain, T., Leung, N., Ailawadhi, S., Reeder, C. B., Lacy, M. Q., Rajkumar, S. V., Kumar, S., Kyle, R. A., Gertz, M. A., Ansell, S. M., & 1 othersKapoor, P., Mar 2023, In: American journal of hematology. 98, 3, p. 432-439 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Waldenstrom Macroglobulinemia 100%
  • Survival 40%
  • Elderly 11%
  • Population 9%
  • Group Psychotherapy 8%

• T-cell phenotype including CD57⁺ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma

  Yang, Z. Z., Kim, H. J., Wu, H., Tang, X., Yu, Y., Krull, J., Larson, D. P., Moore, R. M., Maurer, M. J., Pavelko, K. D., Jalali, S., Pritchett, J. C., Mudappathi, R., Wang, J., Villasboas, J. C., Mondello, P., Novak, A. J. & Ansell, S. M., Dec 2023, In: Blood cancer journal. 13, 1, 124.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Follicular Lymphoma 100%
  • Tumor Microenvironment 84%
  • Helper-Inducer T-Lymphocytes 84%
  • T-Lymphocytes 50%
  • Phenotype 48%

• Venoarterial Extracorporeal Membrane Oxygenation After Autologous Stem Cell Transplantation With Pancytopenia: JACC Patient Care Pathways

  Howick V, J. F., Rezkalla, J. A., Tilbury, T., Mankad, S. V., Bennett, C. E., Herrmann, J., Barsness, G., Ansell, S. M. & Read, M. D., Jul 25 2023, In: Journal of the American College of Cardiology. 82, 4, p. 374-378 5 p.

  Research output: Contribution to journal › Review article › peer-review

  • Pancytopenia 100%
  • Extracorporeal Membrane Oxygenation 94%
  • Stem Cell Transplantation 84%
  • Patient Care 62%
  • Cardiopulmonary Resuscitation 58%

• Venoarterial Extracorporeal Membrane Oxygenation After Autologous Stem Cell Transplantation With Pancytopenia: JACC Patient Care Pathways

  Howick V, J. F., Rezkalla, J. A., Tilbury, T., Mankad, S. V., Bennett, C. E., Herrmann, J., Barsness, G., Ansell, S. M. & Read, M. D., Jul 19 2023, In: JACC: Case Reports. 18, 101913.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Pancytopenia 100%
  • Extracorporeal Membrane Oxygenation 94%
  • Stem Cell Transplantation 84%
  • Patient Care 62%
  • Cardiopulmonary Resuscitation 58%

• Volume preface

  Ansell, S. M., Apr 14 2023, Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice. wiley, Vol. 1. p. xxvi-xxvii

  Research output: Chapter in Book/Report/Conference proceeding › Foreword/postscript
• 2022

  Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS)

  Saw, J. L., Sidiqi, M. H., Ruff, M., Hocker, S., Alkhateeb, H., Ansell, S. M., Bennani, N. N., Dingli, D., Hayman, S. R., Johnston, P. B., Kapoor, P., Kenderian, S. J., Kourelis, T. V., Kumar, S. K., Paludo, J., Shah, M. V., Siddiqui, M. A., Warsame, R., Rosenthal, A., Grill, M., & 6 othersCastro, J. E., Siegel, J., Abdel Rahman, Z. H., Kharfan-Dabaja, M. A., So, E. & Lin, Y., Apr 2022, In: Blood cancer journal. 12, 4, 62.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome

  Chohan, K. L., Young, J. R., Lester, S., Moustafa, M. A., Rosenthal, A., Tun, H. W., Hoppe, B. S., Johnston, P. B., Micallef, I. N., Habermann, T. M. & Ansell, S. M., Jul 26 2022, In: Blood Advances. 6, 14, p. 4241-4250 10 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Combined Modality Therapy 100%
  • Hodgkin Disease 82%
  • Drug Therapy 47%
  • Progression-Free Survival 27%
  • Clinical Trials 13%

• Brentuximab Vedotin in Advanced Hodgkin's Lymphoma. Reply

  Ansell, S. M., Radford, J. & Straus, D. J., Oct 20 2022, In: The New England journal of medicine. 387, 16, p. 1527-1528 2 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study

  Tun, A. M., Khurana, A., Mwangi, R., Link, B. K., Wang, Y., Feldman, A. L., Thompson, C. A., Novak, A. J., Villasboas, J. C., Thanarajasingam, G., Farooq, U., Syrbu, S., Nowakowski, G. S., Witzig, T. E., Ansell, S. M., Rimsza, L. M., Cerhan, J. R., Habermann, T. M. & Maurer, M. J., Sep 13 2022, In: Blood Advances. 6, 17, p. 5210-5221 12 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Rituximab 100%
  • B-Cell Lymphoma 95%
  • Non-Hodgkin's Lymphoma 86%
  • Lymphoma 76%
  • Cause of Death 73%

• Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience

  Bennani, N. N., Tun, A. M., Carson, K. R., Geiger, J. L., Maeda, L. S., Savage, K. J., Rose, J., Pinter-Brown, L., Lunning, M. A., Abramson, J. S., Bartlett, N. L., Vose, J. M., Evens, A. M., Smith, S. M., Horwitz, S. M., Ansell, S. M. & Advani, R. H., May 1 2022, In: Clinical Lymphoma. 22, 5, p. e300-e309

  Research output: Contribution to journal › Article › peer-review

  • Extranodal NK-T-Cell Lymphoma 100%
  • North America 65%
  • Natural Killer T-Cells 45%
  • T-Cell Lymphoma 44%
  • Combined Modality Therapy 38%

• Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience

  Bennani, N. N., Tun, A. M., Carson, K. R., Geiger, J. L., Maeda, L. S., Savage, K. J., Rose, J., Pinter-Brown, L., Lunning, M. A., Abramson, J. S., Bartlett, N. L., Vose, J. M., Evens, A. M., Smith, S. M., Horwitz, S. M., Ansell, S. M. & Advani, R. H., Apr 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, 4, p. e250-e260

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Extranodal NK-T-Cell Lymphoma 100%
  • North America 65%
  • Natural Killer T-Cells 40%
  • T-Cell Lymphoma 39%
  • Combined Modality Therapy 33%

• Chronic lymphocytic leukemia (CLL) with Reed–Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?

  King, R. L., Gupta, A., Kurtin, P. J., Ding, W., Call, T. G., Rabe, K. G., Kenderian, S. S., Leis, J. F., Wang, Y., Schwager, S. M., Slager, S. L., Kay, N. E., Koehler, A., Ansell, S. M., Inwards, D. J., Habermann, T. M., Shi, M., Hanson, C. A., Howard, M. T. & Parikh, S. A., Jan 2022, In: Blood cancer journal. 12, 1, 18.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • B-Cell Chronic Lymphocytic Leukemia 100%
  • Hodgkin Disease 96%
  • Survival 7%
  • Human Herpesvirus 4 6%
  • Retrospective Studies 4%